Association of quantitative MRI features of DCIS with surgical upstaging and recurrence after treatment.

Breast MRI
DOI: 10.1200/jco.2023.41.16_suppl.e12540 Publication Date: 2023-06-04T14:09:31Z
ABSTRACT
e12540 Background: Ductal carcinoma in situ (DCIS) is a common preinvasive breast cancer typically identified on screening mammography. Pure DCIS nonlethal, but 20-25% of cases core biopsy upstage to invasive at surgery and about half progress disease if not treated. As result, most patients undergo excision radiation therapy. score multigene assay that can aid treatment decision-making serve as surrogate marker ipsilateral recurrence (IBR) risk. Breast MRI accurately depict span has potential assess biology IBR We sought the associations advanced quantitative features with upstaging score. Methods: In this IRB-approved single institution prospective clinical trial, recommended for calcifications or those who had residual after yielding pure consented receive multiparametric (dynamic contrast-enhanced diffusion-weighted) prior surgery. The following were obtained: functional tumor volume (FTV), transfer constant (K trans ), extracellular extravascular fraction (v e background parenchymal enhancement (BPE), apparent diffusion coefficient (ADC). Patients biopsy-proven followed through completion determine upstaging. was performed sufficient excision-proven DCIS. Associations evaluated by Spearman’s correlation Wilcoxon rank-sum test. Results: Of 120 enrolled study, 57 (48%) diagnosed biopsy. Fifty-five underwent surgery, 13 whom (24%) upstaged disease. Thirty-eight lesions tissue generate Score. Several associated Score: K (p < 0.01) significantly higher Higher scores lower = 0.04) v 0.05) values. No statistically significant observed between FTV, BPE, ADC Conclusions: This trial suggests may help identify risk IBR. Specifically, an imaging feature vascular permeability ) showed expected positive association Imaging counterintuitive inverse Scores. Future research larger cohorts needed validate these findings, better biological reasons associations, whether be used clinically optimize treatment. Clinical information: NCT03495011 .
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)